Isolator Synergy Clamps (OLL2/OSL2)

The FIRST and ONLY Approved Surgical Device to Treat Atrial Fibrillation

Request More Information

Isolator Synergy Clamp (OSL2/OLL2) shown from the side at an angle against a white background

Isolator Synergy Clamp (OSL2/OLL2) shown from the side against a white background

Isolator Synergy Clamp (OSL2/OLL2) shown from the clamp at an angle against a white background

Product Features

Dual Electrodes
Rigid Steel Shaft
Rigid Parallel Jaws

Features	OSL2	OLL2
Jaw Length	53 mm	65mm
Generator	ASU/ASB, MAG	ASU/ASB, MAG

Isolator Synergy Clamp (OSL2/OLL2) jaws shown at three different degrees of opening against a white background

The Isolator Synergy clamp is the first and only surgical ablation device offered with FDA approval for the treatment of Atrial Fibrillation (Afib) and the only device, either catheter or surgical, to be approved for the treatment of persistent and long-standing persistent Afib.

Isolator Synergy Clamp (OSL2/OLL2) jaws closed against a white background

Efficient Energy Delivery

Uses a dynamic monitoring algorithm that measures the tissue’s response to radio frequency delivery 50 times per second, which results in a custom-made column-shaped lesion specific to a tissue’s length, width and composition.

Diagram showing electrode alignment when the jaws are opened and closed

Parallel Closure and Dual Electrodes

Stainless steel shaft and jaws maintain consistent tissue pressure and precise electrode alignment across entire length of the jaws. The Synergy clamp uses two pairs of electrodes, creating a more robust lesion.

Create Robust Lesions With Isolator Synergy

See how the parallel jaw closure combined with dual electrodes and continuous monitoring create a uniform lesion.

540,000

Patients served with ablation worldwide

20+ Years

Surgical ablation expertise and leadership

Class I

Recommendation by the Society of Thoracic Surgeons for performing concomitant surgical ablation during open heart surgery to fix a coronary or valve

PRODUCT CODES:

OLL2
OSL2

PM-US-0239D-0626-G

The AtriCure Synergy Ablation System is intended to ablate cardiac tissue for the treatment of persistent atrial fibrillation (sustained beyond seven days, or lasting less than seven days but necessitating pharmacologic or electrical cardioversion) or longstanding persistent atrial fibrillation (continuous atrial fibrillation of greater than one year duration) in patients who are undergoing open concomitant coronary artery bypass grafting and/or valve replacement or repair.